Drug Profile
MDX 1411
Alternative Names: MDX-1411Latest Information Update: 17 Jun 2013
Price :
$50
*
At a glance
- Originator Medarex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Renal cancer
Most Recent Events
- 17 Jun 2013 No development reported - Phase-I for Renal cancer in USA (IV)
- 01 Jun 2010 Bristol-Myers Squibb completes a phase I trial in Renal cancer in USA (NCT00656734)
- 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb